Alto Neuroscience prices a $100M public offering at $26.48 per share to fund Phase 3 trials of ALTO-207
ANRO has more than doubled off its 52-week low of $2.5 on elevated volume (4.6× avg).
Summary
Alto Neuroscience priced a $100 million public offering at $26.48 per share, a 7% discount to market, to fund an additional Phase 3 trial of ALTO-207 for treatment-resistant depression. The offering is dilutive but extends cash runway and attracted strong institutional support.
Key Events · Financing and Capital Events · ANRO
-
Public Offering Priced
Alto Neuroscience entered into an underwriting agreement to sell 3,776,436 shares of common stock at $26.48 per share, a 7% discount to the current market price of $28.50.
-
Net Proceeds and Use of Funds
The offering is expected to generate approximately $93.9 million in net proceeds, which will be used to accelerate and expand the clinical development of ALTO-207, including an additional planned Phase 3 trial for treatment-resistant depression, and for general working capital.
-
Dilution Impact
The 3.8 million new shares represent approximately 10% dilution to existing shareholders, but the capital extends the company's cash runway and funds a pivotal clinical program.
-
Underwriter Syndicate
BofA Securities, Stifel, William Blair, Robert W. Baird, JonesTrading, and H.C. Wainwright are acting as joint book-running managers and co-managers, indicating strong institutional demand.
Analysis · ANRO · Life Sciences
Alto Neuroscience has entered into an underwriting agreement to sell 3,776,436 shares at $26.48 each, yielding approximately $93.9 million in net proceeds. Priced at a modest 7% discount to the current $28.50 stock price, the offering reflects strong institutional demand near the 52-week high. The capital will accelerate and expand clinical development of ALTO-207, including an additional Phase 3 trial for treatment-resistant depression—a high-risk, high-reward indication. While the financing extends the company's cash runway and reduces near-term dilution risk, the 3.8 million new shares represent roughly 10% dilution to existing shareholders. A syndicate of reputable underwriters backs the deal, signaling confidence in the pipeline.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANRO was trading at $28.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $983.7M. The 52-week trading range was $2.50 to $28.44. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.